Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 216

1.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*..

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876.

2.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators..

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814.

3.

A novel live-attenuated vaccine candidate for mayaro Fever.

Weise WJ, Hermance ME, Forrester N, Adams AP, Langsjoen R, Gorchakov R, Wang E, Alcorn MD, Tsetsarkin K, Weaver SC.

PLoS Negl Trop Dis. 2014 Aug 7;8(8):e2969. doi: 10.1371/journal.pntd.0002969.

4.

Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep.

Morrill JC, Laughlin RC, Lokugamage N, Pugh R, Sbrana E, Weise WJ, Adams LG, Makino S, Peters CJ.

Vaccine. 2013 Jan 7;31(3):559-65. doi: 10.1016/j.vaccine.2012.10.118.

5.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators., Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624.

6.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators..

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3.

7.

Developing brokered community transportation for seniors and people with disabilities.

Marx J, Davis C, Miftari C, Salamone A, Weise W.

J Gerontol Soc Work. 2010;53(5):449-66. doi: 10.1080/01634372.2010.487886.

PMID:
20603754
8.

The case: a Caucasian male with dark skin, black urine, and acute kidney injury.

Santos AL, Ibrahim G, Mount S, Thomas C, Weise WJ.

Kidney Int. 2009 Dec;76(12):1295-6. doi: 10.1038/ki.2009.388. No abstract available.

9.

Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.

Hutchison AJ, Barnett ME, Krause R, J, Siami GA; Lanthanum Carbonate Study Group..

Clin Nephrol. 2009 Mar;71(3):286-95.

PMID:
19281739
10.

Alendronate-associated focal segmental glomerulosclerosis.

Prikis M, Gibson PC, Weise WJ.

NDT Plus. 2009 Feb;2(1):91-2. doi: 10.1093/ndtplus/sfn164. No abstract available.

11.

Exenatide-associated ischemic renal failure.

Weise WJ, Sivanandy MS, Block CA, Comi RJ.

Diabetes Care. 2009 Feb;32(2):e22-3. doi: 10.2337/dc08-1309. No abstract available.

PMID:
19171732
12.

Acid-base disturbances in gastrointestinal disease.

Gennari FJ, Weise WJ.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1861-8. doi: 10.2215/CJN.02450508. Review.

13.

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.

Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA; SPD405-309 Lanthanum Study Group..

Nephron Clin Pract. 2008;110(1):c15-23. doi: 10.1159/000149239. Erratum in: Nephron Clin Pract. 2008;110(1):c23.

14.

Acute electrolyte and acid-base disorders in patients with ileostomies: a case series.

Weise WJ, Serrano FA, Fought J, Gennari FJ.

Am J Kidney Dis. 2008 Sep;52(3):494-500. doi: 10.1053/j.ajkd.2008.04.015.

PMID:
18562060
15.

When a friend can become an enemy! Recognition and management of metformin-associated lactic acidosis.

Prikis M, Mesler EL, Hood VL, Weise WJ.

Kidney Int. 2007 Nov;72(9):1157-60. No abstract available.

16.

Tolvaptan for hyponatremia.

Weise WJ, Rimmer JM, Hood VL.

N Engl J Med. 2007 Mar 1;356(9):961; author reply 962-3. No abstract available.

17.

Comment on "surprises in threshold antikaon-nucleon physics".

Borasoy B, Nissler R, Weise W.

Phys Rev Lett. 2006 May 19;96(19):199201; author reply 199202. No abstract available.

PMID:
16803147
18.
19.

Coronary artery bypass graft mycotic aneurysms in a dialysis patient.

Geneidy AA, Weise WJ.

Am J Kidney Dis. 2005 Nov;46(5):962-6.

PMID:
16253739
20.

Propylene glycol-induced lactic acidosis in a patient with normal renal function: a proposed mechanism and monitoring recommendations.

Neale BW, Mesler EL, Young M, Rebuck JA, Weise WJ.

Ann Pharmacother. 2005 Oct;39(10):1732-6.

PMID:
16159998
Items per page

Supplemental Content

Loading ...
Support Center